The efficacy of therapy with DPP-4 inhibitors combined with insulin in patients with type 2 diabetes mellitus

par Alexander Sergeevich Ametov, Ekaterina Vladimirovna Karpova
Publié 2011

Clinical implementetion of vildagliptin: data from recent studies comparing incretin-based medications

par Elena Valer'evna Biryukova
Publié 2014

Nanofibrous vildagliptin-eluting stents enhance re-endothelialization and reduce neointimal formation in diabetes: in vitro and in vivo

par Lee CH, Hsieh MJ, Chang SH, Hung KC, Wang CJ, Hsu MY, Juang JH, Hsieh IC, Wen MS, Liu SJ
Publié 2019

Effects of vildagliptin relative to sulfonylureas in Muslim patients with type 2 diabetes fasting during Ramadan: influence of age and treatment with/without metformin in the VIRTU...

par Hassoun AAK, Pathan MF, Medlej RC, Alarouj M, Shaltout I, Chawla MS, Knap D, Vaz JA
Publié 2016

DEVELOPMENT AND VALIDATION OF SPECTROPHOTOMETRIC METHODS FOR THE DETERMINATION AND SPECTROSCOPIC CHARACTERIZATION OF VILDAGLIPTIN USING II -ACCEPTORS IN PHARMACEUTICAL PREPARATIONS

par TEKKELI,SERIFE EVRIM KEPEKCI, BAHADORI,FATEMEH
Publié 2014

Initial investigation of efficacy and safety of a new dipeptidyl peptidase-4 inhibitor, gosogliptin, for type 2 diabetes in Russia

par Lyudmila Viktorovna Nedosugova, Nina Alexandrovna Petunina, Karina Oganesovna Galstyan
Publié 2014

Vildagliptin: the first innovative DDP-4 inhibitor

par Edvin Villkhauer
Publié 2010

Results of a clinical trial of the efficacy and safety of vildagliptin and metformin fixed combination in real clinical practice in Russia (MASTER study)

par N. A. Demidov, M. B. Antsiferov, A. V. Zilov
Publié 2021

Possible applications of gliptins (dipeptidyl peptidase-4 inhibitors) in patients with type 2 diabetes mellitus on the various modes of insulin therapy

par Gagik Radikovich Galstyan, Svetlana Viktorovna Sergeeva
Publié 2015

What are new opportunities for clinical practice the VERIFY study opens and which values for native diabetes patients? Joint conclusion on the advisory board results. November 6, 2...

par Marina V. Shestakova, Mikhail B. Antsiferov, Alexander S. Ametov, Gagik R. Galstyan, Tatiana Y. Demidova, Alexey V. Zilov, Tatiana N. Markova, Nina A. Petunina, Natalya A. Chernikova, Minara S. Shamkhalova
Publié 2020

Expert committee on introduction of incretin-based therapy in Russia: advance and failure

par Editorial team Diabetes Mellitus
Publié 2012

Long-Term Glycaemic Durability of Early Combination Therapy Strategy versus Metformin Monotherapy in Korean Patients with Newly Diagnosed Type 2 Diabetes Mellitus

par Soon-Jib Yoo, Sang-Ah Chang, Tae Seo Sohn, Hyuk-Sang Kwon, Jong Min Lee, Sungdae Moon, Pieter Proot, Päivi M Paldánius, Kun Ho Yoon
Publié 2021

Vildagliptin: optimal control in type 2 diabetes mellitus treatment

par Alexander Sergeevich Ametov
Publié 2015

First Russian DPP-4 inhibitor Gosogliptin comparing to Vildagliptin in type 2 diabetes mellitus patients

par Karina Oganesovna Galstyan, Liudmila Viktorovna Nedosugova, Nina Alexandrovna Petunina, Julia Alexandrovna Trakhtenberg, Natalia Vadimovna Vostokova, Oksana Vladimirovna Karavaeva, Tatiana Evgenievna Chasovskaya
Publié 2016

EDGE study in Russian Federation: efficacy and safety of vildagliptine in comparison with other oral antidiabetic agents in patients with type 2 diabetes mellitus

par Gagik Radikovich Galstyan
Publié 2013